Institut Pasteur Korea Selects ActivityBase™ as its Screening Solution of Choice
News Sep 19, 2006
Institut Pasteur Korea (IP-K), a Research Center located in Seoul, South Korea, has purchased ActivityBase to handle their biology and chemistry data for High Throughput and High Content Screening (HTS/HCS).
IP-K is implementing HCS assays and platforms for Drug Discovery using cell-based models of disease and automated confocal microscopy.
IP-K will use ActivityBase suite to consolidate chemistry information and screening results, including those from microscopy-based screens, in a single Oracle database.
Institut Pasteur Korea decided to purchase ActivityBase as its researchers felt more secure with a system with a proven track record in Drug Discovery.
Dr. Thierry Christophe, the Head of the Screening and Pharmacology lab, has used ActivityBase in previous positions at other companies.
He said, "I am happy to be working with ActivityBase again, as it is a robust and flexible system that I know can deliver the results we need."
"We plan to develop specific data analysis templates for High Content Screens allowing the manipulation of multiplexing data from one single screen."
Neil Kipling, IDBS’ Chairman and CEO, commented, "The increase in HCS and HTS planned by IP-K’s screening group demanded a data management system that could scale up to their requirements, both now and in the future, as well as map closely to their workflow."
"We are delighted to be supporting a centre of excellence in biomedical research and technology development, allowing new drugs to be identified faster and more reliably."
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017